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ABSTRACT 50 
Background Antigen specific IgE binds the Fc receptor I (FcRI) expressed on 51 
several types of immune cells, including dendritic cells (DC). Activation of FcRI on 52 
DCs in atopics has been shown to modulate immune responses that potentially 53 
contribute to asthma development. However, the extent to which DC subsets differ in 54 
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FcRI expression between atopic children with or without asthma is currently not 55 
clear.  56 
This study aimed to analyse the expression of FcRI on peripheral blood mononuclear 57 
cells (PBMC) from atopic children with and without asthma, and non-atopic/non-58 
asthmatic age-matched healthy controls. 59 
Methods We performed multiparameter flow cytometry on PBMC from 391 children 60 
across three community cohorts and one clinical cohort based in Western Australia. 61 
Results We confirmed expression of FcRI on basophils, monocytes, plasmacytoid 62 
and conventional DCs, with higher proportions of all cell populations expressing 63 
FcRI in atopic compared to non-atopic children. Further, we observed that levels of 64 
FcRI expression was elevated across plasmacytoid and conventional DC as well as 65 
basophils in atopic asthmatic compared to atopic non-asthmatic children also after 66 
adjusting for serum IgE levels.  67 
Conclusion Our data suggest that the expression pattern of FcRI on DC and 68 
basophils differentiates asthmatic and non-asthmatic atopic children. Given the 69 
significant immune modulatory effects observed as a consequence of FcRI 70 
expression, this altered expression pattern is likely to contribute to asthma pathology 71 
in children.  72 
 73 
Key words FcεRI expression, dendritic cells, basophils, monocytes, atopic asthma, 74 
IgE, childhood asthma, PBMC, flow cytometry 75 
 76 
BACKGROUND 77 
Allergic IgE sensitisation and early life respiratory infections are major risk factors 78 
for development of atopic asthma during childhood1. Asthma affects 300 million 79 
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people, consists of several phenotypes and atopic asthma is the most common in 80 
children. The disease manifests initially as wheeze which is triggered at the time of 81 
respiratory viral infection, but in the majority of children the wheezy phenotype is 82 
only transient and resolves during the preschool years, whereas in a smaller subset 83 
dominated by sensitized children it persists and intensifies and eventually develops 84 
into full-blown atopic asthma. At the time of puberty, asthma transitions from being 85 
most common in boys to becoming more common in females2.  86 
 87 
IgE sensitization is characterised by induction of allergen-specific T helper 2 (Th2) 88 
immune memory and the production of corresponding specific IgE. Allergen specific 89 
IgE binds Fcε receptors that are expressed on several cell types within the airways and 90 
circulation including mast cells, basophils, monocytes and dendritic cells (DC)3. Fcε 91 
receptor I (FcεRI) binds IgE with high affinity and consists of three subunits; the IgE 92 
binding α-subunit and the signalling/regulatory ȕ and Ȗ subunits. Mast cells and 93 
basophils express a αȕȖ2 tetrameric complex, whereas DC expresses a αȖ2 trimeric 94 
complex4. Crosslinking of IgE-bound FcεRI complexes by allergen leads to release of 95 
inflammatory mediators by mast cells/basophils and this is largely dependent on 96 
signal amplification by the ȕ-subunit5. Thus, the function of trimeric FcεRI on DCs 97 
and monocytes is more complex. On the one hand conventional DC (cDC) utilize 98 
surface FcεRI expression to enhance their allergen capture functions6, which can 99 
result in multi-logfold increased capacity to re-activate Th2-memory cells7 but have 100 
also been reported to be involved in IgE clearance through internalisation of serum 101 
IgE8 and induction of immune modulatory mechanisms such as tolerance9. 102 
Conversely, cross-linking of FcεRI on plasmacytoid DC (pDC) results in reduced type 103 
I-interferon signalling and impaired anti-viral responses10,11. Expression of FcεRI on 104 
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pDCs and cDC has been reported to be dependent on serum IgE levels3, and in 105 
sensitised children with elevated levels of specific IgE (above 0.35 IU/mL), 106 
respiratory viral infections are often more prevalent/severe compared to non-atopic 107 
children as reviewed12. The proportion of FcεRI+ DCs, and FcεRI expression 108 
intensity, is generally higher in atopic and/or asthmatic individuals compared to 109 
healthy controls but variation exists between studies8,11, The association of FcεRI 110 
expression and total serum IgE levels appears strongest for basophils and pDCs8,13. 111 
 112 
Although FcεRI expression has been reported to be elevated in atopic and/or 113 
asthmatic individuals compared to healthy controls13-15, there are currently few studies 114 
that have investigated whether FcεRI expression across cell populations within the 115 
PBMC fraction can differentiate atopic asthmatics from atopic but non-asthmatic 116 
individuals. In the current study we aimed to identify and characterise FcεRI 117 
expressing cell populations in atopic children with or without asthma and healthy 118 
controls across four different allergy/asthma cohorts based in Western Australia. Our 119 
findings suggest that FcεRI expression may have clinical relevance to the pathology 120 
of childhood asthma, and has potential to be used as a biomarker related to disease 121 
susceptibility and phenotype. 122 
 123 
METHODS 124 
Study cohorts 125 
A subset of school-age individuals (age range 7-15 years) from four independent 126 
cohorts based in Perth, Western Australia, were analysed. The participant numbers 127 
and clinical parameters are summarised in Table I. The Childhood Asthma Study 128 
(CAS) cohort is a birth cohort which investigated respiratory infections in children 129 
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from families with a history of allergy or asthma and thus with a high risk for 130 
developing atopic disease at the age of 10 years16. The Western Australian Twin study 131 
of Child Health (WATCH) was established as a population-based twin register to 132 
examine the genetics of asthma and attention deficit hyperactivity disorder. This was 133 
extended to include a follow-up subsample of participant families enriched for (but 134 
not exclusively) physician-diagnosed asthmatics17 at the median age of 10 years. The 135 
Western Australian Pregnancy Cohort (Raine) is a large (>2000 children) unselected 136 
general birth cohort where approximately 10% of participants developed asthma for a 137 
period during their first 14 years of life18,19. From this cohort, 79 atopic individuals 138 
were included in the analysis and selected so that 40 individuals also had an asthma 139 
diagnosis at the age of 14 years. Peripheral blood samples from the CAS, WATCH, 140 
and Raine cohorts were collected when the children did not display any clinical 141 
symptoms of airway disease. The Mechanism of Acute Viral Respiratory Infection in 142 
Children (MAVRIC) cohort enrols children with median age of 9 years, who seek 143 
emergency medical attention with an acute respiratory wheeze at Princess Margaret 144 
Hospital in Perth, Australia20. MAVRIC cohort samples were collected during an 145 
acute wheezy respiratory episode requiring hospitalization, with follow-up samples 146 
collected ≥ 4 weeks later at convalescence. All work on human samples was carried 147 
out after informed consent was given in accordance with the declaration of Helsinki. 148 
 149 
Clinical parameters and measurements 150 
Atopy was defined as a positive skin prick test (SPT, wheal size ≥γmm) or levels of 151 
specific IgE above 0.35 IU/mL as measured using ImmunoCap (Phadia, Sweden) for 152 
any of the most common aeroallergens in the Perth region including house dust mite 153 
(HDM, Dermatophagoides pteronyssinus), cat dander, dog dander, Alternaria 154 
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alternata, Aspergillus spp., cockroach, Rye grass (Lolium perenne), mixed grass and 155 
mixed mould. SPT, total IgE and specific IgE were measured in the CAS, Raine and 156 
MAVRIC cohorts; SPT and total IgE were measured in the WATCH study. Current 157 
asthma was defined as (i) ever having physician diagnosed asthma, (ii) a wheezy 158 
episode within the last 12 months and (iii) current use of asthma medication, such as 159 
short acting adrenic 2 agonists. This definition of asthma excluded children who 160 
only wheeze at a very young age. 161 
 162 
PBMC collection, storage and thawing  163 
Peripheral blood was collected and processed within 2 hours (CAS and Raine), or 18 164 
hours (WATCH). For the acute cohort (MAVRIC), samples were collected within 72 165 
hours of presentation to Princess Margaret Hospital (Perth, Western Australia) and 166 
processed within 18 hours20. PBMCs were obtained using LymphoprepTM (Axis-167 
Shield, Norway) and cryopreserved in liquid nitrogen. Frozen PBMC were thawed as 168 
previously21. Identical PBMC isolation, cryopreservation, storage and thaw protocols 169 
were applied to all cohorts. Viability was assessed using trypan blue exclusion and 170 
was above 80%. 171 
 172 
Flow cytometry analysis 173 
Approximately 1x106 thawed PBMCs were stained as previously described21. The 174 
same FACS staining panel and protocol was used for all cohorts. Antibodies were 175 
titrated and a single batch was used across all samples within a cohort. Additionally, 176 
unstained and FcεR1 isotype stained samples (pooled per run) were included as 177 
controls for each staining and acquisition run. Samples were acquired using the LSR-178 
Fortessa platform with FACSDiva software (BD Bioscience, Franklin Lakes, NJ). 179 
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Quality control was preformed prior to each cytometry run for all cohorts; CS&T 180 
beads (BD) to ensure standardised setup and technical performance, and Rainbow 181 
calibration particles (BD) to determine alignment and track performance across 182 
detection channels and lasers. Following acquisition, data were analysed using 183 
FlowJo 10.3 (FlowJo, Ashland, Ore) and FlowSOM in R (v3.2.4)22. 184 
 185 
Statistical Analysis 186 
The statistical significance of difference between two groups was estimated using 187 
Student’s t-test or the Mann-Whitney U test depending on the data distribution; for 188 
comparison of three groups the Kruskal-Wallis test followed by Dunn’s post test was 189 
used; for comparison of paired samples Wilcoxon’s Signed rank test was used and for 190 
comparison of categorical data between groups, Pearson’s χ2 test was used. 191 
Adjustment for IgE levels was calculated using Nominal logistic regression for 192 
current asthma within atopic individuals using log(serum IgE levels) and proportion 193 
of FcεRIα+ subset or log(FcεRIα MFI). Experimental and technical variation was 194 
minimised within and between cohorts, however the presence of latent variables 195 
between cohorts is a common consideration inherent to cross-cohort studies. To 196 
account for this when combining cohorts to compare FcεRIα expression, each cohort 197 
was normalised with respect to the 10% of subjects with the highest MFI for each 198 
cohort and cell type. The 10% threshold was considered reasonable as it captures the 199 
characteristic plateau observed in all cell types for the highest FcεRIα expressing 200 
individuals (Fig S3). Additionally, complete randomisation of subjects with respect to 201 
asthmatic status within the Raine cohort was not possible due to the experimental 202 
design. For analysis of FcεRIα MFI in the Raine cohort, expression was normalised to 203 
the run-specific isotype control. This consideration was not required for the CAS, 204 
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
  9 
WATCH and MAVRIC cohorts determined by the consistency of the isotype controls 205 
(data not shown). All statistical analysis was performed using JMP 13 (SAS, NSW, 206 
Australia) and data was visualised using Prism 7.0a (GraphPad, La Jolla, Calif). 207 
 208 
RESULTS 209 
To identify FcεRI expressing cell types in the PBMC fraction, we used a 12-colour 210 
flow cytometry panel21 (Fig S1) and an unsupervised learning approach (FlowSOM)22 211 
overlayed with manual gating to determine key cell populations (Fig 1A-B) and 212 
expression of FcεRIα across these populations (Fig 1C). Using this approach, we 213 
identified FcεRIα expression on pDCs, monocytes, cDCs and basophils (Fig 1D), as 214 
previously demonstrated23. 215 
 216 
To investigate the association between atopy and asthma with FcεRIα expression, we 217 
compared proportion and level of FcεRIα expression in above identified cell 218 
populations from (i) non-atopic/non-asthmatic, (ii) atopic/non-asthmatic or (iii) 219 
atopic/asthmatic individuals across the CAS, WATCH and Raine cohorts. Compared 220 
to non-atopic/non-asthmatic individuals, there was a significantly higher proportion of 221 
FcεRIα+ pDCs in both atopic groups from the WATCH and CAS cohorts, as well as 222 
increased proportion of FcεRIα+ monocytes in atopic/non-asthmatic compared to non-223 
atopic in the WATCH or compared to atopic/asthmatic in the Raine cohort (Fig 2A).  224 
FcεRIα expression amongst FcεRIα+ pDC, cDC, monocyte and basophil populations 225 
displayed a progressive gradation of FcεRIα expression from non-atopics to 226 
atopic/non-asthmatics, and ultimately to atopic/asthmatics across all cohorts (Fig 2B). 227 
As the cohorts consisted of different proportions of individuals with the clinical 228 
phenotypes of interest, the power of each individual cohort to detect differences 229 
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between some groups differed, and therefore we additionally combined the cohorts as 230 
part of the analyses performed as a way of interrogating trends observed within each 231 
individual cohort. Once combined, we observed an increased proportion of FcεRIα+ 232 
pDCs in atopic/asthmatics compared to atopic/non-asthmatics (Fig 2C) and we also 233 
observed significantly greater FcεRIα expression levels on FcεRIα+ pDCs, cDCs and 234 
basophils in atopic individuals (non-asthmatic and asthmatic) compared to non-235 
atopic/non-asthmatics (Fig 2D). Amongst the cohorts the atopic/asthmatics stand out 236 
most prominently by this criterion in Raine cohort (Fig 2A-B), and this may be a 237 
reflection of relative atopic disease chronicity given that these subjects represent the 238 
oldest group tested. We further investigated whether FcεRIα expression was 239 
influenced by biological sex (Fig S2A-C) or use of corticosteroid medication within 240 
asthmatic individuals (Fig S3A-D) observing that asthmatic individuals on 241 
corticosteroids expressed higher levels of FcεRIα compared to individuals on other 242 
asthma medication. 243 
 244 
Given the well established correlations of FcεRIα expression and total IgE serum 245 
levels, which we also observed (Fig S4A-D), we compared total serum IgE between 246 
our groups after combining cohorts (Fig 3A). Atopics (non-asthmatic and asthmatic) 247 
displayed significantly higher serum IgE levels compared to non-atopic/non-248 
asthmatics. In addition, atopic/asthmatics also displayed higher levels compared to 249 
atopic/non-asthmatics. Therefore, to determine if the observed differences in 250 
proportion of FcεRIα+ pDCs between atopic/non-asthmatics and atopic/asthmatics as 251 
well as the increased levels of FcεRIα expression were dependent of total IgE levels, 252 
we adjusted for IgE levels using logistic regression on atopic individuals with asthma 253 
as the outcome. We observed that both the proportion of FcεRIα+ pDCs (Fig 3B) as 254 
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well as increased level of expression on FcεRIα+ pDCs, cDCs and basophils (Fig 3C) 255 
were associated with asthma independently of serum IgE levels, suggesting the 256 
operation of a mechanism by which FcεRIα expression is associated with asthma 257 
which goes beyond the control of IgE production. 258 
 259 
We finally sought to assess the impact of asthma exacerbations on circulating 260 
FcεRIα+ cell subsets in atopic children. Through the MAVRIC cohort, we recruited 261 
subjects presenting at hospital during an acute wheezing illness. For each subject, an 262 
acute sample was assessed against a paired convalescent sample obtained once 263 
symptoms had resolved several weeks later (Fig 4). Plasmacytoid DC, cDC, and 264 
basophil cell numbers were significantly decreased during respiratory exacerbation 265 
compared to convalescence (Fig 4A-B), consistent with their likely exit from 266 
circulation and migration to sites of inflammation in the airways and their subsequent 267 
participation in the local host immunoinflammatory response. No correlation between 268 
systemic steroid administration and cell numbers were observed (Fig S5A-D). 269 
Together this suggests that these subsets are systemically influenced by wheezing 270 
airway disease in atopic individuals. 271 
 272 
DISCUSSION 273 
In the present study, we have systematically characterised the expression of FcεRI on 274 
cells in the PBMC fraction in non-atopic and atopic children with and without asthma. 275 
Our findings are broadly consistent with upregulated expression of FcεRI on both 276 
effector (basophil) and regulatory (myeloid, especially pDC/cDC) populations and 277 
this upregulation is associated with current atopic asthma. Interstingly, the correlation 278 
of FcεRI expression and total IgE levels is not as strong as previously reported24, 279 
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potentially due to the young age of the participants. There are also indications that 280 
these subsets migrate to the airways during an acute exacerbation25. However given 281 
the small sample size and potential interference from administration of systemic 282 
steroids, this requires further investigation. 283 
 284 
Regarding underlying mechanism(s), enhanced FcεRI expression on basophils 285 
equates to reducing the allergen-exposure threshold required for triggering IgE-286 
mediated degranulation and attendant acute inflammation, but the implications of 287 
comparable upregulation on myeloid cells are more complex. Circulating cDC are the 288 
immediate source of precursors required to renew the airway mucosal DC network 289 
which turns over rapidly during infections/exacerbations26, and their migration to this 290 
tissue pre-armed with FcεRI would increase the intensity of acute aeroallergen-291 
specific Th2-effector responses and promote expansion of corresponding Th2-292 
memory populations. A similar mechanism applies to circulating monocytes which 293 
traffic to airways following allergen challenge27 and further give rise to monocyte 294 
derived DC28. However, expression of FcεRI on monocytes does not appear to 295 
separate atopic/non-asthmatic and asthmatic individuals in this data set. 296 
 297 
Plasmacytoid DCs are recognised as the major producers of type I interferons, the 298 
most important mediators of host viral defence29. Consequently, pDCs are a likely 299 
candidate to bridge the gap between IgE sensitisation and respiratory viral infection as 300 
major asthmatic risk factors and may have a central role in regulating airway 301 
inflammation during asthma exacerbations triggered by viruses29. In a subsample 302 
from the COAST cohort, an increased proportion of pDCs expressing FcεRI in atopic 303 
asthmatic children was observed compared to non-atopic non-asthmatics children11. 304 
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However, no significant difference was observed when compared to allergic non-305 
asthmatics, possibly a result of sample size. Notably within the COAST study, 306 
allergic asthmatic children demonstrated significantly impaired ability to produce type 307 
I interferons following FcεRI cross-linking with IgE in the presence of human 308 
rhinovirus, indicating that FcεRI expressing pDCs may have a reduced ability to 309 
initiate viral defence11. Omalizumab treatment decreases circulating IgE levels and 310 
associated FcεRI cell surface expression. Importantly, omalizumab treatment reduces 311 
asthma exacerbation frequency and results in restored type I interferon response to 312 
rhinovirus30.  313 
 314 
In conclusion, our findings support the previous reports outlining an important role 315 
for FcεRI in atopic disease. Our study also suggest that FcεRI expression may be used 316 
to identify children with maximal susceptibility to allergic asthma and thus identify 317 
kids that may benefit the most from intervention therapies targeting atopy or 318 
allergic/Th2 mediated inflammation. 319 
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 419 
 420 
TABLES 421 
Table 1 – Clinical and demographic features for the respective cohorts. 422 
 CAS WATCH Raine MAVRIC p† 
Number of 
individuals, n 
(% of total 
119 
(32.0%) 
174 
(46.8%) 
79 
(21.2%) 
19 
n/a 
n/a 
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individuals) 
Males, n (%) 71  
(59.7%) 
100  
(57.5%) 
44  
(55.7%) 
12 
(63.2%) 
0.91 
Age, median 
years (range) 
10.1  
(10.0-10.7) 
10.6 
(7.2-13.0) 
14.1  
(13.5-14.9) 
8.8  
(6.9-13.2) 
<0.001 
Total IgE, 
median 
IU/mL 
(range) 
166.8 
(0-9892.1) 
61.5 
(1.0-747.0) 
378.9 
(38.3-
5206.6) 
585.3 
(123.7-
2342.1) 
<0.001 
SPT+, n (%) 74  
(62.2%) 
132/172 
(76.7%)‡ 
65/75 
(86.7%)‡ 
11/13 
(84.6%)‡ 
<0.001 
Atopy (SPT+ 
or sIgE > 0.35 
IU/mL), n 
(%) 
98 
(82.4%) 
132 
 (75.9%) 
79  
(100%) 
19  
(100%) 
<0.001 
Current 
Asthma, n 
(%) 
7  
(5.9%) 
28 
(16.1%) 
40  
(50.6%) 
19  
(100%) 
<0.001 
Additional 
atopic 
disease§ 
within atopic 
individuals, n 
(%) 
63 
(64.3%) 
73/90 
(81.1%)‡ 
51 
(64.6%) 
n/a 0.02 
Admitted to 
hospital with 
acute wheeze, 
n (%) 
n/a n/a n/a 15/17 
 (88.2%)‡ 
n/a 
Hours from 
last systemic 
corticosteroid 
administration 
(1 mg/kg) to 
blood 
collection, 
median 
(range) 
n/a n/a n/a 4.1 
 (0.4-14.8)‡, 
n = 13 
n/a 
Respiratory 
viral infection 
positive, n 
(%) 
n/a n/a n/a 11/14  
(78.6%)‡ 
n/a 
Total PBMC 
fraction cell 
1.9  
(0.8-4.2) 
1.1 
(0.6-5.1) 
1.5  
(0.8-4.1) 
0.5  
(0.3-2.3) 
<0.001 
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count, x 
106/mL 
median 
(range) 
†p-values of statistical difference between cohorts using either Kruskal-Wallis or 423 
Pearson’s χ2 test depending on characteristics of the data. 424 
‡data missing from some individuals. 425 
§additional atopic diseases were allergic rhinitis or eczema within last 12 months. 426 
 427 
FIGURE LEGENDS 428 
Figure 1 429 
A Algorithm (FlowSOM) based clustering of cells found within the PBMC fraction 430 
followed by manual classification using surface marker expression. B Cell numbers 431 
per mL of blood of the major cell populations of individuals included in the WATCH 432 
study. C-D Mapping of FcRI expression across the cell populations identified by 433 
FlowSOM (C) and representative gates of FcRI+ cel subsets (D) Representative 434 
figures from one individual are shown in A, C and D. In B, data is displayed as 435 
median, 25-75% percentile and range, n=174. 436 
 437 
Figure 2 438 
A-D Proportion (A,C) and expression of FcRI (B,D) on FcRI+ cells within each 439 
cell type found in PBMC fraction in non-atopic/non-asthmatic, atopic/non-asthmatic 440 
or atopic/asthmatic individuals from each cohort (A-B) or combined (C-D). 441 
Significance of difference was calculated using Kruskal-Wallis test followed by 442 
Dunn’s post test or Mann-Whitney’s for comparisons of two groups in the Raine 443 
cohort and indicated as; *** p<0.001, ** p<0.01, * p<0.05. Data are displayed as 444 
median, 25-75% percentile and range, CAS n(non-atopic/non-asthmatic)=21, CAS n(atopic/non-445 
This	article	is	protected	by	copyright.	All	rights	reserved
Au
th
or
 M
an
us
cr
ip
t
  18 
asthmatic)=91 and CAS n(atopic/asthmatic)=7. WATCH n(non-atopic/non-asthmatic)=42, WATCH 446 
n(atopic/non-asthmatic)=104 and WATCH n(atopic/asthmatic)=28. Raine n(atopic/non-asthmatic)=39 and 447 
Raine n(atopic/asthmatic)=40. combined n(non-atopic/non-asthmatic)=63, combined n(atopic/non-448 
asthmatic)=235 and combined n(atopic/asthmatic)=75. 449 
 450 
Figure 3 451 
A Total IgE serum levels in non-atopic/non-asthmatic, atopic/non-asthmatic or 452 
atopic/asthmatic individuals in the combined cohorts. B-C Association of FcRI+ 453 
cells proportion in PBMC fraction (log odds ratio 95% CI; B) or normalised 454 
expression levels of FcRI on FcRI+ subsets (log expression level 95% CI; C) to 455 
current asthma within atopics of the combined cohorts, adjusted for log(serum IgE). 456 
Data in A are displayed as median, 25-75% percentile and range, combined n(non-457 
atopic/non-asthmatic)=63, combined n(atopic/non-asthmatic)=235 and combined n(atopic/asthmatic)=75. 458 
In B-C the estimated effect size (log odds ratio) for asthma among atopics  95% CI 459 
per unit increase in % positive cells (B) or in log(expression level) (C) is displayed, 460 
n(atopic)=309. 461 
 462 
Figure 4 463 
A-B Concentrations of cells in the PBMC fraction at exacerbation and convalescence 464 
(A) or fold change of cell concentration in the same individual during exacerbation 465 
compared to convalescence (B). Significance of difference on paired samples was 466 
calculated using Wilcoxon’s Signed ranks test and indicated as; *** p<0.001. Data 467 
are displayed as individual values, median, 25-75% percentile and range, n=19. 468 
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